Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can we get to 0.15 and get rid of jammy today? Glory is on the horizon.
Getting closer to sayonara threshold…
Actually it’s within 3 business days, as a regulation norm. If we don’t, FDA punted or we received a CRL or request for additional adjustments to be made.
On one of them he stated that margins would be a challenge, but that he believes they will still get to where he would like.
I believe poster is clarifying that dopamine agonist was filed last Dec and due for FDA decision any day now, while slightly larger antimetabolite isn’t due for approval until late Feb. Nothing more, nothing less.
I think you are referring to dopamine agonists coming up this month vs antimetabolite, which isn’t due for another couple months and not the Prasco deal. I could care less about either of these tiny drugs as they aren’t going to add much value to the company, but will take up mfg utilization. With couple big drugs in pipeline, Elite is being faced with question of slimming down pipeline to delay need for separate mfg location or keep smaller drugs expediting need for more mfg space driving more costs and smaller financial return, but helping diversify portfolio little bit at a time.
Just for kicks, you can also layer on Prasco Adderall XR contract mfg deal that starts 1/1/24.
Should be getting news any day now regarding FDA submission for generic Vyvanse.
I see a spread of 0.10/0.104. Been like that most of morning.
Also, R&D is a potential synergy by the acquirer. If they leave Elite as is the company must continue to invest in R&D. It’s seen as an ongoing need. However, the acquirer could stop R&D, combine with theirs, but that simply means the R&D shifts buckets and you drop a few heads. Bottom line, it doesn’t get excluded. Through all acquisitions I have seen and been part of, R&D has never been ignored.
It also is what drives incremental future growth, which is what the PE multiple is all about - future expected growth.
Earnings include R&D. You are just making crap up again dude. You can’t ignore a significant company expense. As of today they are profitable, but barely. They will continue to invest in R&D. Don’t be ignorant to facts. That only gets you gov’t jobs. Oh wait, you worked for the gov’t. Lol
Basic math here has one huge flaw. PE is price to EARNINGS, not revenue. This would assume that Elite incurs no expense whatsoever. Taking an earnings ratio even at a very healthy 30% gives you a drastically lower figure. Last time I checked Elite didn’t get API for free, have a volunteer sales and admin force or get free rent and utilities. Don’t skip over the overhead, variable costs, ongoing R&D & other fixed costs needed to support growth, which will happen.
Completely get it. The glory of being able to mute people on Ihub and ignore their posts.
I really don’t care what IB does. It doesn’t change the financial outlook, cash flow, upcoming deals, FDA approvals or drug launches. If anyone invests what they read on a message board they are taking on some serious risk.
Holy cow! You are right! 0.01% of total outstanding shares sold at a 2% discount to yesterdays closing. Sell everything!!
Please sell all you can. Please.
Looks like you just created a new ID for this post. Kudos for the creativity.
That’s not going to work here. May want to check out the SEC filings. Company has been CFP for a while now. Would love to see shorts get burned.
Who doesn’t like a crazy dog barking during a conference call?
I think we’re still at least a few years out from acquisition. We have too much going on near term. Nasrat has also hinted at another drug family about a year ago that we haven’t heard anything about yet (cardio related?). Would be interesting to see if he resurrects SequestOx v2.0 mid-term knowing opioid scripts will likely return. Buyback program to be implemented with R&D/excess cash split, upgrading to NASDAQ, etc. If all goes well with current irons in the fire, we are sitting pretty. Not sure how big Burel is going to be, but had huge volume previously as auth generic. We are not the auth generic, but I’m cautiously optimistic that this will be a solid way to get decent traction with XR that has eluded us so far despite the significant market size.
Positive Vyvanse BE study wasn’t enough followed by FDA submission or deal with Prasco Burel that starts 1/1 for Adderall XR or how about Generic Oxy filing accepted by FDA?
I think you mean Vigabatrin launch. It’s already approved. Pyros has been prepping for launch for months.
Would be nice to see this in likely chrono order. Got some nice things coming up, no pun intended re goathumpers.
Thx for confirming. Didn’t reference filing.
I believe 1.3B is total approved share count, not issued and outstanding.
Nice article and reinforces push to build safety net with critical medicines. We did get a loan in the past that we didn’t have to pay back. That was the PPA loan during Covid that was forgiven.
Share price and acquisitions are based in financial formulas, guardrails and future potential within reason. Investors need to learn those basics. It’s not twisting. It’s finance 101 basics.
I would love to see the math behind 2% of a $10B market (inaccurate market size when Vyvanse is approved anyways). Y guess is that you are basing a huge PE on gross rev, not profit. Don’t forget cost structure and reasonable PE for generic industry.
So what you are a saying is that in our current $2B market being at a dime, with a $5B market we will be at a quarter. Vyvanse wont be a $5B market when we enter. That market will soon be shrinking by the day and will shrink significantly further once all the generics hit after 180-day stay is completed.
Adderalls are close to $2B market by themselves. Adderall IR has done well, XR on the other hand…
Market size isn’t everything, but it is important when factoring market capture and penetration.
12B market cap? That’s not even in the ballpark of reality.
I believe it shot up to 0.97 over a very short time frame.
Going to break a dime today and keep inching up?
NDA margins vs ANDA margins. Much different market and story. Company is now consistently profitable, but forward PE is much smaller in generic world.
It will not be a $5B market when Vyvanse is approved and it will be an even smaller market when they launch. Keep an eye on it and you’ll see.
You forgot the decimal.
Applesauce is all I have to say…
Elite won’t be able to get much more quota for XR, per Nasrat’s words. Prasco/Burel on the other hand…
First SequestOx wasn’t a great product, the CEO knew it and had to submit a 2.0 version. Had FDA gone route of forcing non-ADT off the market, which is where they were leaning, Elite would have been the leader among the opioid space on getting a significant market share vs 5-10%.
Please note that Adderall ER has a total market of like $1.5B and yet where do Elite’s Adderall XR sales sit today? Less than 1% of the total market. Burel is going to open doors here, but Elite barely scratched the surface. Let’s be cognizant of total market capture as total market means nothing if you can’t sell your way out of a paper bag (Lannett).
It will be under Burel label. No longer authorized generic.